WI OAK PRO1: STRONG OXIDATIVE AND METABOLIC THERAPY
Wisconsin Oak. Stage IV pancreatic adenocarcinoma with liver metastases, diagnosed Oct 2017. Treatment start date: Aug 6 2018. Treatment end date: NA. Core treatment elements: interstitial photodynamic therapy (PDT), IV 3BP, IV salinomycin, low-dose chemotherapies, mind/body methods. Core support: IV low-dose continuous 2-DG, Dr Hercbergs thyroid protocol, oncotherm-style localized hyperthermia, targeted fasting, tetrandrine. Numerous secondary supports. Dramatic results in first 2 months.
"Wisconsin Oak" was diagnosed with Stage IV pancreatic adenocarcinoma on Oct 3, 2017, with a primary tumor 5.1 x 3.5 cm in the tail of the pancreas and several liver lesions. His CA 19-9 marker was 47,000 at diagnosis.
Working with a local oncologist, WI Oak went on the aggressive first-line standard chemotherapy, FOLFIRINOX (administered at X dose every 3 weeks) from Nov 2017 through April 6, 2018. At the end of April, his oncologist removed oxaliplatin (continued with FOLFIRI) out of concern for potential future nerve damage. On April 17th, 2018, his CA 19-9 was 3,440, the liver metastases appeared stable and the primary tumor had shrunk significantly (3.3 x 3.4 cm). He continued with FOLFIRI through June 6th. Starting in November and continuing to the present he also has been taking, daily, an array of oral therapeutic agents including metformin, celocoxib, LDN, curcumin, and beta glucan. In addition, he fasted for 2.5 days around each chemotherapy treatment. More information and data about this treatment is available here.
His next CA 19-9 test, on June 25th, came back at 17,100. Although at that time the tumors had not changed size, he did not resume FOLFIRI at this point on the advice of his oncologist. Over the next week, his CA 19-9 went up by 27% and then over the next 3 weeks by 33% a week. On July 25th, his CA 19-9 number was 50,000. In addition, the volume of his largest liver tumor had more than doubled over 4 weeks. Of note, from June 6th until August 13th - over 2 months - he experienced a “rest” period, and did not receive any aggressive therapies.
In early August, WI Oak and his family chose a strong pro-oxidant and metabolic approach with the focus of reversing the rapid liver tumor growth. This approach used IV low-dose continuous 2-DG synergistically with a range of aggressive therapies, including interstitial photodynamic therapy (PDT), oncotherm-style localized hyperthermia, 3BP, salinomycin, and low-dose chemotherapies (800 mg/m^2 Gemcitabine for the first three treatments, then 25 g vit C, 500 mg/m^2 Gemcitabine + 80 mg/m^2 Abraxane). WI Oak also used a combination of supportive therapies, including tetrandrine, IV vitamin C, HBOT prior to 3BP, sildafinil/viagra, metformin, IV curcumin, IV mistletoe, IV EGCG, metformin, doxycycline, mebendazole, and a combination of cytomel and methimazole following the thyroid therapy developed by Dr Aleck Hercbergs. Finally, he used a number of other oral therapeutic agents that are probably of lower significance. To receive all these therapies, WI Oak and his wife moved to Canada for a two-month period to work with an excellent doctor who could provide the oncotherm-style hyperthermia and the interstitial photodynamic therapy. This doctor was open to using 2-DG and is now in correspondence with the Lampidis foundation about using it with other patients.
As indicated in Graphs 1 and 2, above, WI Oak succeeded in reversing the rapid tumor growth during and after his treatment in Canada. By one assay technique, his CA 19-9 dropped by almost 95% over 2 months. Not only was the CA 19-9 response to this combined therapy much more rapid than the response to his first-line chemotherapy, in fact the CA 19-9 fell more rapidly than it rose during the two month "rest" period. CT and PET scans on Oct 10th showed no new metastases and the disappearance of a few small liver metastases that had showed up in July. Also, the Oct 10th PET compared to one from July 25 showed decrease in intensity of the primary tumor and most importantly, "significant decrease in FDG uptake [from 8.1 to 4] within the large liver tumor, with mainly large photopenic region in the center of the lesion and a moderately FDG avid rim." This result is consistent with necrosis in the body of the tumor.
While it is difficult to assign positive impact to individual therapies, given how many therapies he was engaging in, WI Oak's response is better than expected for the chemotherapy alone, or for photodynamic therapy alone. Over the next several months, WI Oak plans to continue low dose chemotherapy along with salinomycin, 3BP and 2-DG in a 3-week pattern similar to the last 3 weeks. When he moves to any other high-level cancer treatment strategy, he will almost certainly continue to use 2-DG in a low-dose continuous fashion.
WI Oak, who weighs 85 kg, escalated his 2-DG use over time, starting with 1 gram over 24 hours, moving to 2 grams over 48 hours, plateauing at 3 grams over 48 hours for a period of time, and then moving up to 4 grams over 48 hours. Given that losing weight is not a concern for him, he has also combined multi-day fasting with 2-DG. This combination did accelerate some of the fatigue and switch-to-ketosis symptoms he normally experienced during fasting. In general, however, he has tolerated the 2-DG well. He and his wife also became comfortable administering it themselves, procuring it from various sources, including companies that supply research labs. This was necessary in order for them to continue treatment when they returned home to Wisconsin. They were inspired by the story of Marcos and his wife posted on cancertreatmentresearch. They hope their story can bring similar inspiration to others and can add momentum to bringing 2-DG into phase 2 clinical trials and wide-spread adoption by clinicians in the United States and around the world.